Menu
Back to Journals » Lung Cancer: Targets and Therapy
Lung Cancer: Targets and Therapy
- View all (141)
- Volume 12, 2021 (3)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Journal Articles:
- 141 records -
Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
Giustini N, Bazhenova L
Lung Cancer: Targets and Therapy 2021, 12:21-34
Published Date: 25 March 2021
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
Tan AC, Loh TJ, Kwang XL, Tan GS, Lim KH, Tan DSW
Lung Cancer: Targets and Therapy 2021, 12:11-20
Published Date: 18 March 2021
Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling
Yu D, Zhao W, Vallega KA, Sun SY
Lung Cancer: Targets and Therapy 2021, 12:1-10
Published Date: 5 February 2021
Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
Lang D, Haslinger W, Akbari K, Scala M, Hergan B, Asel C, Horner A, Wass R, Brehm E, Kaiser B, Lamprecht B
Lung Cancer: Targets and Therapy 2020, 11:113-121
Published Date: 18 December 2020
Clinical Outcomes of Proton Beam Therapy for Ground-Glass Opacity-Type Lung Cancer
Nagata I, Ogino T, Arimura T, Yoshiura T
Lung Cancer: Targets and Therapy 2020, 11:105-111
Published Date: 9 October 2020
A Comprehensive Review of Contemporary Literature for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer and Their Toxicity
Lee CS, Sharma S, Miao E, Mensah C, Sullivan K, Seetharamu N
Lung Cancer: Targets and Therapy 2020, 11:73-103
Published Date: 7 October 2020
Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
Yang W, Chen N, Li L, Chen X, Liu X, Zhang Y, Cui J
Lung Cancer: Targets and Therapy 2020, 11:59-71
Published Date: 7 September 2020
Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer
Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S, Horikawa S, Ikeue T, Sugita T
Lung Cancer: Targets and Therapy 2020, 11:53-57
Published Date: 12 July 2020
Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature
Peri M, Fazio N
Lung Cancer: Targets and Therapy 2020, 11:41-52
Published Date: 8 July 2020
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the ALK Gene Have Durable Responses to ALK Kinase Inhibitors
Schrock AB, Madison R, Rosenzweig M, Allen JM, Erlich RL, Wang SY, Chidiac T, Reddy VS, Riess JW, Yassa AE, Shakir A, Miller VA, Alexander BM, Venstrom J, McGregor K, Ali SM
Lung Cancer: Targets and Therapy 2020, 11:33-39
Published Date: 17 April 2020
Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
Kauffmann-Guerrero D, Huber RM
Lung Cancer: Targets and Therapy 2020, 11:27-31
Published Date: 2 March 2020
Incidence of ROS1-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients
Mehta A, Saifi M, Batra U, Suryavanshi M, Gupta K
Lung Cancer: Targets and Therapy 2020, 11:19-25
Published Date: 24 February 2020
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in ALK-Rearranged NSCLC: A Report of Two Cases
Zhu VW, Nagasaka M, Kubota T, Raval K, Robinette N, Armas O, Al-Holou W, Ou SI
Lung Cancer: Targets and Therapy 2020, 11:13-18
Published Date: 14 January 2020
The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer
Cheng YY, Rath EM, Linton A, Yuen ML, Takahashi K, Lee K
Lung Cancer: Targets and Therapy 2020, 11:1-11
Published Date: 8 January 2020
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives
Inoue H, Okamoto I
Lung Cancer: Targets and Therapy 2019, 10:161-170
Published Date: 3 January 2020
Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer
Mix M, Tanny S, Nsouli T, Alden R, Chaudhari R, Kincaid R, Rosenbaum PF, Bogart JA, Aridgides P
Lung Cancer: Targets and Therapy 2019, 10:151-159
Published Date: 20 December 2019
Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma
Baldovini C, Rossi G, Ciarrocchi A
Lung Cancer: Targets and Therapy 2019, 10:131-149
Published Date: 5 December 2019
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JCH, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SHI
Lung Cancer: Targets and Therapy 2019, 10:125-130
Published Date: 13 November 2019
Landscape on CT screening for lung cancer in Asia
Triphuridet N, Henschke C
Lung Cancer: Targets and Therapy 2019, 10:107-124
Published Date: 30 September 2019
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
Nagasaka M, Abdallah N, Crosby M, Thummala N, Patel D, Wozniak AJ, Gadgeel S, Abrams J, Sukari A
Lung Cancer: Targets and Therapy 2019, 10:95-105
Published Date: 12 September 2019
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
Facchinetti F, Friboulet L
Lung Cancer: Targets and Therapy 2019, 10:87-94
Published Date: 9 September 2019
TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, Yakirevich E, Ali SM, Patel NR
Lung Cancer: Targets and Therapy 2019, 10:81-86
Published Date: 15 August 2019
Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers
Stratmann JA, Sebastian M
Lung Cancer: Targets and Therapy 2019, 10:67-80
Published Date: 1 July 2019
Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients
Masykura N, Zaini J, Syahruddin E, Andarini SL, Hudoyo A, Yasril R, Ridwanuloh A, Hidajat H, Nurwidya F, Utomo A
Lung Cancer: Targets and Therapy 2019, 10:57-66
Published Date: 17 June 2019
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
Weinberg F, Gadgeel S
Lung Cancer: Targets and Therapy 2019, 10:47-56
Published Date: 4 June 2019
Pain management in patients with malignant mesothelioma: challenges and solutions
Saunders J, Ashton M, Hall C, Laird B, MacLeod N
Lung Cancer: Targets and Therapy 2019, 10:37-46
Published Date: 2 April 2019
Targeting RET-rearranged non-small-cell lung cancer: future prospects
Bronte G, Ulivi P, Verlicchi A, Cravero P, Delmonte A, Crinò L
Lung Cancer: Targets and Therapy 2019, 10:27-36
Published Date: 20 March 2019
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
Zhu VW, Schrock AB, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2019, 10:21-26
Published Date: 12 March 2019
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET
Lung Cancer: Targets and Therapy 2019, 10:11-20
Published Date: 8 February 2019
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
Kate S, Chougule A, Joshi A, Noronha V, Patil V, Dusane R, Solanki L, Tiwrekar P, Trivedi V, Prabhash K
Lung Cancer: Targets and Therapy 2019, 10:1-10
Published Date: 29 January 2019
Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation
Zhu VW, Schrock AB, Bosemani T, Benn BS, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2018, 9:111-116
Published Date: 8 November 2018
Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer
Aridgides P, Nsouli T, Chaudhari R, Kincaid R, Rosenbaum PF, Tanny S, Mix M, Bogart J
Lung Cancer: Targets and Therapy 2018, 9:103-110
Published Date: 5 November 2018
Silicosis and lung cancer: current perspectives
Sato T, Shimosato T, Klinman DM
Lung Cancer: Targets and Therapy 2018, 9:91-101
Published Date: 26 October 2018
Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation
Abdallah N, Nagasaka M, Abdulfatah E, Shi D, Wozniak AJ, Sukari A
Lung Cancer: Targets and Therapy 2018, 9:85-90
Published Date: 25 October 2018
Amifostine- and chemoradiotherapy-related esophagitis in small cell lung cancer: a single institutional series and literature update
Pollock AE, Shinn L, Anderson R, Butler S, Pollock J
Lung Cancer: Targets and Therapy 2018, 9:79-84
Published Date: 10 September 2018
Hypersensitivity in ALK-positive lung cancers exposed to ALK inhibitors: a case of successful switch to an alternative ALK inhibitor and systematic review of the literature
Deng L, Sharma J, Ravera E, Halmos B, Cheng H
Lung Cancer: Targets and Therapy 2018, 9:73-77
Published Date: 6 September 2018
1-, 3-, and 5-year survival among early-stage lung cancer patients treated with lobectomy vs SBRT
Albano D, Bilfinger T, Nemesure B
Lung Cancer: Targets and Therapy 2018, 9:65-71
Published Date: 24 August 2018
Comprehensive review of fetal adenocarcinoma of the lung
Ricaurte LM, Arrieta O, Zatarain-Barrón ZL, Cardona AF
Lung Cancer: Targets and Therapy 2018, 9:57-63
Published Date: 23 August 2018
Prophylactic cranial irradiation in small-cell lung cancer: update on patient selection, efficacy and outcomes
Manapov F, Käsmann L, Roengvoraphoj O, Dantes M, Schmidt-Hegemann NS, Belka C, Eze C
Lung Cancer: Targets and Therapy 2018, 9:49-55
Published Date: 16 August 2018
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burden
Parikh AR, Ali SM, Schrock AB, Albacker LA, Miller VA, Stephens PJ, Crilley P, Markman M
Lung Cancer: Targets and Therapy 2018, 9:45-47
Published Date: 18 May 2018
Role and inhibition of GLI1 protein in cancer
Mastrangelo E, Milani M
Lung Cancer: Targets and Therapy 2018, 9:35-43
Published Date: 27 March 2018
Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients
Syahruddin E, Wulandari L, Sri Muktiati N, Rima A, Soeroso N, Ermayanti S, Levi M, Hidajat H, Widjajahakim G, Utomo ARH
Lung Cancer: Targets and Therapy 2018, 9:25-34
Published Date: 23 March 2018
Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives
Donovan EK, Swaminath A
Lung Cancer: Targets and Therapy 2018, 9:13-23
Published Date: 16 March 2018
Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
Veldore VH, Choughule A, Routhu T, Mandloi N, Noronha V, Joshi A, Dutt A, Gupta R, Vedam R, Prabhash K
Lung Cancer: Targets and Therapy 2018, 9:1-11
Published Date: 3 January 2018
Bevacizumab in the treatment of NSCLC: patient selection and perspectives
Russo AE, Priolo D, Antonelli G, Libra M, Mccubrey JA, Ferraù F
Lung Cancer: Targets and Therapy 2017, 8:259-269
Published Date: 14 December 2017
Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K
Lung Cancer: Targets and Therapy 2017, 8:249-257
Published Date: 8 December 2017
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
Klempner SJ, Mehta P, Schrock AB, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2017, 8:241-247
Published Date: 6 December 2017
Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
Wojcik E, Kulpa JK
Lung Cancer: Targets and Therapy 2017, 8:231-240
Published Date: 28 November 2017
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer
Schuette W, Schneider CP, Engel-Riedel W, Schumann C, Kohlhaeufl M, Serke MHU, Hoeffken G, Kortsik C, Reck M
Lung Cancer: Targets and Therapy 2017, 8:217-229
Published Date: 6 November 2017
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C
Lung Cancer: Targets and Therapy 2017, 8:207-216
Published Date: 30 October 2017
Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan
Isobe H, Mori K, Minato K, Katsura H, Taniguchi K, Arunachalam A, Kothari S, Cao X, Kato T
Lung Cancer: Targets and Therapy 2017, 8:191-206
Published Date: 24 October 2017
Comparative effectiveness and safety of nab-paclitaxel plus carboplatin vs gemcitabine plus carboplatin in first-line treatment of advanced squamous cell non-small cell lung cancer in a US community oncology setting
Mudad R, Patel MB, Margunato-Debay S, Garofalo D, Lal LS
Lung Cancer: Targets and Therapy 2017, 8:179-190
Published Date: 19 October 2017
Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinib
Jain RK, Chen H
Lung Cancer: Targets and Therapy 2017, 8:169-177
Published Date: 13 October 2017
Prognostic value of soluble major histocompatibility complex class I polypeptide-related sequence A in non-small-cell lung cancer – significance and development
Cascone R, Carlucci A, Pierdiluca M, Santini M, Fiorelli A
Lung Cancer: Targets and Therapy 2017, 8:161-167
Published Date: 10 October 2017
EGFR T790M: revealing the secrets of a gatekeeper
Ko B, Paucar D, Halmos B
Lung Cancer: Targets and Therapy 2017, 8:147-159
Published Date: 9 October 2017
Proton beam therapy in non-small cell lung cancer: state of the art
Harada H, Murayama S
Lung Cancer: Targets and Therapy 2017, 8:141-145
Published Date: 23 August 2017
Clinical staging of malignant pleural mesothelioma: current perspectives
Bonomi M, De Filippis C, Lopci E, Gianoncelli L, Rizzardi G, Cerchiaro E, Bortolotti L, Zanello A, Ceresoli GL
Lung Cancer: Targets and Therapy 2017, 8:127-139
Published Date: 18 August 2017
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R
Lung Cancer: Targets and Therapy 2017, 8:109-125
Published Date: 18 August 2017
Chronic obstructive pulmonary disease in patients with lung cancer: prevalence, impact and management challenges
Spyratos D, Papadaki E, Lampaki S, Kontakiotis T
Lung Cancer: Targets and Therapy 2017, 8:101-107
Published Date: 7 August 2017
New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer
Niki M, Yokoi T, Kurata T, Nomura S
Lung Cancer: Targets and Therapy 2017, 8:91-99
Published Date: 3 August 2017
Psychosocial challenges for patients with advanced lung cancer: interventions to improve well-being
Lehto RH
Lung Cancer: Targets and Therapy 2017, 8:79-90
Published Date: 28 July 2017
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
Seetharamu N, Preeshagul IR, Sullivan KM
Lung Cancer: Targets and Therapy 2017, 8:67-78
Published Date: 13 July 2017
Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
Cobo M, Gutiérrez V, Villatoro R, Trigo JM, Ramos I, López O, Ruiz M, Godoy A, López I, Arroyo M
Lung Cancer: Targets and Therapy 2017, 8:57-66
Published Date: 12 July 2017
Detection of ROS1 rearrangement in non-small cell lung cancer: current and future perspectives
Rossi G, Jocollé G, Conti A, Tiseo M, Zito Marino F, Donati G, Franco R, Bono F, Barbisan F, Facchinetti F
Lung Cancer: Targets and Therapy 2017, 8:45-55
Published Date: 7 July 2017
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma
Jamil MO, Jerome MS, Miley D, Selander KS, Robert F
Lung Cancer: Targets and Therapy 2017, 8:39-44
Published Date: 12 June 2017
Exhaled breath analysis for the early detection of lung cancer: recent developments and future prospects
Nardi-Agmon I, Peled N
Lung Cancer: Targets and Therapy 2017, 8:31-38
Published Date: 17 May 2017
Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K
Lung Cancer: Targets and Therapy 2017, 8:21-30
Published Date: 22 February 2017
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
Thakur MK, Wozniak AJ
Lung Cancer: Targets and Therapy 2017, 8:13-19
Published Date: 13 February 2017
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
Somasundaram A, Burns TF
Lung Cancer: Targets and Therapy 2017, 8:1-11
Published Date: 11 January 2017
Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
Legius B, Van Den Broecke S, Muylle I, Ninane V
Lung Cancer: Targets and Therapy 2016, 7:149-152
Published Date: 30 November 2016
Lung cancer in Brazil: epidemiology and treatment challenges
de Sá VK, Coelho JC, Capelozzi VL, Azevedo SJ
Lung Cancer: Targets and Therapy 2016, 7:141-148
Published Date: 14 November 2016
Oligometastatic non-small-cell lung cancer: current treatment strategies
Richard PJ, Rengan R
Lung Cancer: Targets and Therapy 2016, 7:129-140
Published Date: 4 November 2016
Radiation-induced esophagitis in lung cancer
Baker S, Fairchild A
Lung Cancer: Targets and Therapy 2016, 7:119-127
Published Date: 13 October 2016
Electromagnetic navigation bronchoscopy: clinical utility in the diagnosis of lung cancer
Seijo LM
Lung Cancer: Targets and Therapy 2016, 7:111-118
Published Date: 12 October 2016
Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K
Lung Cancer: Targets and Therapy 2016, 7:99-110
Published Date: 24 August 2016
Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
Tran PN, Klempner SJ
Lung Cancer: Targets and Therapy 2016, 7:91-97
Published Date: 18 July 2016
Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives
Giroux Leprieur E, Fallet V, Cadranel J, Wislez M
Lung Cancer: Targets and Therapy 2016, 7:83-90
Published Date: 17 June 2016
Fatigue in lung cancer patients: symptom burden and management of challenges
Carnio S, Di Stefano RF, Novello S
Lung Cancer: Targets and Therapy 2016, 7:73-82
Published Date: 9 May 2016
Modern management of malignant pleural mesothelioma
Patel SC, Dowell JE
Lung Cancer: Targets and Therapy 2016, 7:63-72
Published Date: 3 May 2016
High expression of AKR1C1 is associated with proliferation and migration of small-cell lung cancer cells
Tian H, Li X, Jiang W, Lv C, Sun W, Huang C, Chen R
Lung Cancer: Targets and Therapy 2016, 7:53-61
Published Date: 2 May 2016
Monitoring and management of lung cancer patients following curative-intent treatment: clinical utility of 2-deoxy-2-[fluorine-18]fluoro-d-glucose positron emission tomography/computed tomography
Sawada S, Suehisa H, Ueno T, Sugimoto R, Yamashita M
Lung Cancer: Targets and Therapy 2016, 7:45-51
Published Date: 27 April 2016
Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
Minami S, Ogata Y, Ihara S, Yamamoto S, Komuta K
Lung Cancer: Targets and Therapy 2016, 7:35-44
Published Date: 5 April 2016
Optimal delivery of follow-up care following pulmonary lobectomy for lung cancer
Chen YY, Huang TW, Chang H, Lee SC
Lung Cancer: Targets and Therapy 2016, 7:29-34
Published Date: 30 March 2016
miRNA-21 as a novel therapeutic target in lung cancer
Markou A, Zavridou M, Lianidou ES
Lung Cancer: Targets and Therapy 2016, 7:19-27
Published Date: 2 March 2016
HSP90 as a novel molecular target in non-small-cell lung cancer
Esfahani K, Cohen V
Lung Cancer: Targets and Therapy 2016, 7:11-17
Published Date: 1 March 2016
Nutrition support and dietary interventions for patients with lung cancer: current insights
Kiss N
Lung Cancer: Targets and Therapy 2016, 7:1-9
Published Date: 27 January 2016
Epiregulin as a therapeutic target in non-small-cell lung cancer
Sunaga N, Kaira K
Lung Cancer: Targets and Therapy 2015, 6:91-98
Published Date: 12 October 2015
Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small- cell lung cancer: a retrospective study
Minami S, Ogata Y, Yamamoto S, Komuta K
Lung Cancer: Targets and Therapy 2015, 6:83-90
Published Date: 25 September 2015
First-line treatment of advanced ALK-positive non-small-cell lung cancer
Gandhi S, Chen H, Zhao Y, Dy GK
Lung Cancer: Targets and Therapy 2015, 6:71-82
Published Date: 18 September 2015
Targeting PD-1/PD-L1 in lung cancer: current perspectives
González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, Rosell R
Lung Cancer: Targets and Therapy 2015, 6:55-70
Published Date: 31 July 2015
Non-small-cell lung carcinoma: role of the Notch signaling pathway
Barse L, Bocchetta M
Lung Cancer: Targets and Therapy 2015, 6:43-53
Published Date: 26 June 2015
Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
Burns MW, Kim ES
Lung Cancer: Targets and Therapy 2015, 6:35-42
Published Date: 15 May 2015
AXL receptor tyrosine kinase as a therapeutic target in NSCLC
Okimoto RA, Bivona TG
Lung Cancer: Targets and Therapy 2015, 6:27-34
Published Date: 30 April 2015
Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
Minami S, Kijima T
Lung Cancer: Targets and Therapy 2015, 6:13-25
Published Date: 29 January 2015
Hapten-enhanced therapeutic effect in advanced stages of lung cancer by ultra-minimum incision personalized intratumoral chemoimmunotherapy therapy
Yu BF, Lu YF, Gao F, Jing P, Han W, Zhang PC, Liu GL, Ru N, Cui GH, Xu XH, Sun CL, Guan CJ, Che YB, Wu YL, Ma ZL, Fu Q, Liu J, Wang HY
Lung Cancer: Targets and Therapy 2015, 6:1-11
Published Date: 7 January 2015
Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
Karachaliou N, Rosell R
Lung Cancer: Targets and Therapy 2014, 5:73-79
Published Date: 13 November 2014
Staging lung cancer: role of endobronchial ultrasound
Inage T, Nakajima T, Yoshino I
Lung Cancer: Targets and Therapy 2014, 5:67-72
Published Date: 4 November 2014
Hypofractionated stereotactic body radiation therapy for elderly patients with stage IIB–IV nonsmall cell lung cancer who are ineligible for or refuse other treatment modalities
Karam SD, Horne ZD, Hong RL, McRae D, Duhamel D, Nasr NM
Lung Cancer: Targets and Therapy 2014, 5:59-66
Published Date: 3 October 2014
Clinical potential of nintedanib for the second-line treatment of advanced non-small-cell lung cancer: current evidence
Rothschild SI
Lung Cancer: Targets and Therapy 2014, 5:51-57
Published Date: 1 September 2014
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
Stasi I, Cappuzzo F
Lung Cancer: Targets and Therapy 2014, 5:43-50
Published Date: 28 August 2014
New options in the management of intractable ALK(+) metastatic non-small-cell lung cancer
Weise AM, Gadgeel S
Lung Cancer: Targets and Therapy 2014, 5:35-42
Published Date: 6 August 2014
Graphic tobacco warning labels – an improper solution?
Salvi JD
Lung Cancer: Targets and Therapy 2014, 5:33-34
Published Date: 12 July 2014
The voice of postsurgical lung cancer patients regarding supportive care needs
Hoffman AJ, Brintnall RA, von Eye A, Cooper J, Brown JK
Lung Cancer: Targets and Therapy 2014, 5:21-31
Published Date: 28 April 2014
Gastroesophageal junction adenocarcinoma displays abnormalities in homologous recombination and nucleotide excision repair
Dewalt RI, Kesler KA, Hammoud ZT, Baldridge L, Hattab EM, Jalal SI
Lung Cancer: Targets and Therapy 2014, 5:11-20
Published Date: 15 February 2014
Prevalence of driver mutations in non-small-cell lung cancers in the People’s Republic of China
Gou LY, Wu YL
Lung Cancer: Targets and Therapy 2014, 5:1-9
Published Date: 12 February 2014
Potential toxicity and safety evaluation of nanomaterials for the respiratory system and lung cancer
Vlachogianni T, Fiotakis K, Loridas S, Perdicaris S, Valavanidis A
Lung Cancer: Targets and Therapy 2013, 4:71-82
Published Date: 27 November 2013
Emerging treatments in lung cancer – targeting the RLIP76 molecular transporter
Goldfinger LE, Lee S
Lung Cancer: Targets and Therapy 2013, 4:61-69
Published Date: 5 November 2013
Practical management of NSCLC patients with long-term bevacizumab treatment: a report of four cases
Herder GJM, Codrington H, Colder CD, Aerts JG
Lung Cancer: Targets and Therapy 2013, 4:55-59
Published Date: 11 October 2013
Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
Suda K, Mitsudomi T
Lung Cancer: Targets and Therapy 2013, 4:43-53
Published Date: 15 August 2013
Robotic stereotactic body radiation therapy for elderly medically inoperable early-stage non-small cell lung cancer
Karam SD, Horne ZD, Hong RL, Baig N, Gagnon GJ, McRae D, Duhamel D, Nasr NM
Lung Cancer: Targets and Therapy 2013, 4:35-42
Published Date: 7 August 2013
EGFR mutations in patients with lung adenocarcinoma in southwest China: are G719S/A and L861Q more likely detected in tumors derived from smokers?
Wang QS, Mou JH, Yang X, He Y, Li ZP, Luo QY, Li YQ, Lin L, Ma Y, Xiao HL
Lung Cancer: Targets and Therapy 2013, 4:27-33
Published Date: 1 July 2013
MET overexpression and gene amplification in NSCLC: a clinical perspective
Landi L, Minuti G, D'Incecco A, Salvini J, Cappuzzo F
Lung Cancer: Targets and Therapy 2013, 4:15-25
Published Date: 19 June 2013
Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy
Sugiura Y, Nemoto E, Kawai O, Ohkubo Y, Fusegawa H, Kaseda S
Lung Cancer: Targets and Therapy 2013, 4:9-14
Published Date: 10 June 2013
Targeted inhibition in tumors with ALK dependency
Kwak EL, Clark JW, Shaw AT
Lung Cancer: Targets and Therapy 2013, 4:1-8
Published Date: 10 January 2013
Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
Berghmans T, Remmelink M, Awada A
Lung Cancer: Targets and Therapy 2012, 3:91-99
Published Date: 18 December 2012
Lung cancer in women
Barrera-Rodriguez R, Morales-Fuentes J
Lung Cancer: Targets and Therapy 2012, 3:79-89
Published Date: 17 December 2012
Association of p21 Ser31Arg and p53 Arg72Pro polymorphisms with lung cancer risk in CAPUA study
Souto-García A, Fernández-Somoano A, Pascual T, Álvarez-Avellón SM, Tardón A
Lung Cancer: Targets and Therapy 2012, 3:69-78
Published Date: 22 November 2012
MET targeted therapy for lung cancer: clinical development and future directions
Feng Y, Ma PC
Lung Cancer: Targets and Therapy 2012, 3:53-67
Published Date: 10 August 2012
Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis
Fragoulakis VF, Pallis AG, Kaitelidou DK, Maniadakis NM, Georgoulias VG
Lung Cancer: Targets and Therapy 2012, 3:43-51
Published Date: 16 July 2012
Non-small cell lung cancer: the era of targeted therapy
Antonoff MB, D'Cunha J
Lung Cancer: Targets and Therapy 2012, 3:31-41
Published Date: 3 July 2012
Update on biomarkers for the detection of lung cancer
Jantus-Lewintre E, Usó M, Sanmartín E, Camps C
Lung Cancer: Targets and Therapy 2012, 3:21-29
Published Date: 12 June 2012
A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer
Yokoi T, Tamaki T, Shimizu T, Nomura S
Lung Cancer: Targets and Therapy 2012, 3:15-20
Published Date: 18 May 2012
Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer
Zienolddiny S, Skaug V
Lung Cancer: Targets and Therapy 2012, 3:1-14
Published Date: 30 December 2011
Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer
Takeda M, Okamoto I, Nishimura Y, Nakagawa K
Lung Cancer: Targets and Therapy 2011, 2:59-67
Published Date: 14 October 2011
Afatinib treatment in advanced non-small cell lung cancer
Hurwitz JL, Scullin P, Campbell L
Lung Cancer: Targets and Therapy 2011, 2:47-57
Published Date: 7 October 2011
Experience with carboplatin and etoposide maintenance chemotherapy in patients with extensive stage small cell lung cancer
Siddiqi A, Bahrain H, Auerbach M
Lung Cancer: Targets and Therapy 2011, 2:41-45
Published Date: 29 August 2011
Effectiveness of maintenance treatments for nonsmall cell lung cancer
Eadens MJ, Robinson SI, Price KA
Lung Cancer: Targets and Therapy 2011, 2:29-39
Published Date: 22 July 2011
Emerging treatment options in the management of non-small cell lung cancer
Filosso PL, Sandri A, Oliaro A, Filippi AR, Cassinis MC, Ricardi U, Lausi P, Asioli S, Ruffini E
Lung Cancer: Targets and Therapy 2011, 2:11-28
Published Date: 8 June 2011
Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer
Serena Ricciardi, Silverio Tomao, Filippo de Marinis
Lung Cancer: Targets and Therapy 2011, 2:1-9
Published Date: 20 December 2010
Dyspnea in lung cancer patients: a systematic review
Ganesan Kathiresan, Reynold F Clement, Meera T Sankaranarayanan
Lung Cancer: Targets and Therapy 2010, 1:141-150
Published Date: 23 November 2010
Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines
Aaron N Nguyen, Paul W Hollenbach, Normand Richard, et al
Lung Cancer: Targets and Therapy 2010, 1:119-140
Published Date: 10 September 2010
Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells
Ulrike Olszewski, Robert Zeillinger, Klaus Geissler, et al
Lung Cancer: Targets and Therapy 2010, 1:107-117
Published Date: 6 September 2010
The role of maintenance pemetrexed in the treatment of non-small-cell lung cancer
Saeed Rafii, Michael H Cullen
Lung Cancer: Targets and Therapy 2010, 1:101-106
Published Date: 30 July 2010
Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients
Jean Jacques Dugoua, Ping Wu, Dugald Seely, et al
Lung Cancer: Targets and Therapy 2010, 1:85-100
Published Date: 9 July 2010
Circulating tumor cells (CTCs) in lung cancer: current status and future perspectives
Fumihiro Tanaka, Kazue Yoneda, Seiki Hasegawa
Lung Cancer: Targets and Therapy 2010, 1:77-84
Published Date: 7 July 2010
Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis
Matthew A Gubens, Heather A Wakelee
Lung Cancer: Targets and Therapy 2010, 1:63-76
Published Date: 16 June 2010
Shifting the paradigm for maintenance therapy in advanced non-small-cell lung cancer
Barbara Melosky
Lung Cancer: Targets and Therapy 2010, 1:53-62
Published Date: 9 June 2010
Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer
Caroline Wilson, Sarah J Danson
Lung Cancer: Targets and Therapy 2010, 1:37-51
Published Date: 13 May 2010
Drug resistance in lung cancer
Manish Shanker, David Willcutts, Jack A Roth, et al
Lung Cancer: Targets and Therapy 2010, 1:23-36
Published Date: 13 May 2010
Refining the treatment of advanced nonsmall cell lung cancer
Shin Ogita, Antoinette J Wozniak
Lung Cancer: Targets and Therapy 2010, 1:9-22
Published Date: 4 May 2010
Maintenance therapy for metastatic non-small-cell lung cancer – the role of pemetrexed
Youval Katz, Robert A Somer
Lung Cancer: Targets and Therapy 2010, 1:1-7
Published Date: 12 April 2010